Zinc bioavailability

Zinc bioavailability is a physiological concept rather than a specific molecular target; it represents the proportion of dietary zinc that is absorbed and utilized by the body (Lönnerdal, 2000, PubMed). The process is primarily regulated by the SLC39A (ZIP) family of transporters, particularly ZIP4 (SLC39A4) in the small intestine, which facilitates the uptake of zinc from the lumen into enterocytes (NIH Office of Dietary Supplements, 2022). Conversely, the SLC30A (ZnT) family of transporters mediates the efflux of zinc from the cytosol to the extracellular space or into organelles (Kambe et al., 2015, Physiological Reviews). Bioavailability is heavily influenced by dietary ligands; for example, phytates found in grains and legumes can inhibit zinc absorption by forming insoluble complexes, while certain organic acids and animal proteins may enhance it (King et al., 2000, Journal of Nutrition). Clinically, modulating zinc bioavailability is essential for treating zinc deficiency and genetic disorders like acrodermatitis enteropathica, where the ZIP4 transporter is mutated (Uptodate, 2023). Therapeutic interventions typically involve high-dose zinc supplementation or the use of ionophores to bypass standard transport limitations.

Other names

Zinc absorptionFractional zinc absorptionZinc homeostasisZinc status

Increasing the luminal concentration of elemental zinc or modulating transporters like ZIP4 to facilitate intestinal uptake.